Announcement on Supplementing the Notice of the First Extraordinary General Meeting of 2026 and Adding Provisional Proposals

Wuhan Easy Diagnosis Biomedicine Co., Ltd.·July 31, 2026·11 pages

✨ AI Summary

Wuhan Mind Biological Technology Co., Ltd. is supplementing its notice for the first extraordinary general meeting of 2026. The meeting will be held on August 13, 2026, to discuss additional proposals submitted by the controlling shareholder, Ms. Chen Lili. These proposals concern a major asset restructuring.

Summary generated by AI · Always verify with source document

Exchange Summary

EGM CHANGE

Further to our previous message on 25 July 2026 about the Company's 1st Extraordinary General Meeting of 2026, the Company announced on 03 August 2026 the following changes made with regard to the said meeting: Additional items to be voted: 1. The transaction is in compliance with relevant laws and regulations 2. Transaction plan 2.1. Overall plan of the transaction 2.2. Underlying assets 2.3. Transaction counterparties 2.4. Transaction consideration 2.5. Source of funds for the transaction 2.6. Arrangement for payment of the transaction consideration 2.7. Arrangement for the profits and losses during the transitional period 2.8. Arrangement for the accumulated retained profits 2.9. Performance commitments, and reward and compensation arrangement 2.10. Contractual obligations and liabilities for breach of contract of handling the transfer of the ownership of relevant assets 2.11. Valid period of the resolution 3. The transaction does not constitute a connected transaction 4. The transaction constitutes a major assets restructuring 5. Relevant agreements on the transaction to be signed 6. The Company's share price fluctuation before the first release of the restructuring plan 7. The transaction is in compliance with Article 11 and not applicable to Articles 43 and 44 of the Management Measures on Major Assets Restructuring of Listed Companies 8. The transaction is in compliance with Article 4 of Listed Companies Regulation Guidance No. 9 - Regulatory Requirements for Planning and Implementing Major Assets Restructuring of Listed Companies 9. The transaction does not constitute a listing by restructuring as defined by Article 13 in the Management Measures on Major Assets Restructuring of Listed Companies 10. The circumstances as provided for by Article 12 of the Listed Companies Regulation Guidelines No. 7 - Regulation of Abnormal Stock Trading in Listed Companies Related to Major Assets Restructuring do not apply to the transaction parties 11. Diluted immediate return after the transaction, filling measures, and relevant commitments 12. Audit report, pro forma review report and asset evaluation report related to the transaction 13. Independence of the evaluation institution, rationality of the evaluation hypothesis, correlation between the evaluation method and evaluation purpose, and fairness of the evaluated price 14. Pricing basis of the transaction and the rationality 15. Completeness and compliance of the legal procedure of the transaction and effectiveness of the legal documents submitted 16. Confidentiality measures and system adopted for the transaction 17. Statement on assets purchase and sale within 12 months prior to the transaction 18. Full authorization to the board to handle matters regarding the transaction 19. Statement on whether there is a direct or indirect paid employment of other third-party institutions or individuals for the transaction 21. Audit report with an extended period and pro forma audit report related to the transaction 22. Report (revised draft) on major assets purchase and its summary 23. Termination of some projects financed with raised funds and change of the purpose of some raised funds Other information remains unchanged. All the proposals of the meeting are sequenced as follows: 1. The transaction is in compliance with relevant laws and regulations 2. Transaction plan 2.1. Overall plan of the transaction 2.2. Underlying assets 2.3. Transaction counterparties 2.4. Transaction consideration 2.5. Source of funds for the transaction 2.6. Arrangement for payment of the transaction consideration 2.7. Arrangement for the profits and losses during the transitional period 2.8. Arrangement for the accumulated retained profits 2.9. Performance commitments, and reward and compensation arrangement 2.10. Contractual obligations and liabilities for breach of contract of handling the transfer of the ownership of relevant assets 2.11. Valid period of the resolution 3. The transaction does not constitute a connected transaction 4. The transaction constitutes a major assets restructuring 5. Relevant agreements on the transaction to be signed 6. The Company's share price fluctuation before the first release of the restructuring plan 7. The transaction is in compliance with Article 11 and not applicable to Articles 43 and 44 of the Management Measures on Major Assets Restructuring of Listed Companies 8. The transaction is in compliance with Article 4 of Listed Companies Regulation Guidance No. 9 - Regulatory Requirements for Planning and Implementing Major Assets Restructuring of Listed Companies 9. The transaction does not constitute a listing by restructuring as defined by Article 13 in the Management Measures on Major Assets Restructuring of Listed Companies 10. The circumstances as provided for by Article 12 of the Listed Companies Regulation Guidelines No. 7 - Regulation of Abnormal Stock Trading in Listed Companies Related to Major Assets Restructuring do not apply to the transaction parties 11. Diluted immediate return after the transaction, filling measures, and relevant commitments 12. Audit report, pro forma review report and asset evaluation report related to the transaction 13. Independence of the evaluation institution, rationality of the evaluation hypothesis, correlation between the evaluation method and evaluation purpose, and fairness of the evaluated price 14. Pricing basis of the transaction and the rationality 15. Completeness and compliance of the legal procedure of the transaction and effectiveness of the legal documents submitted 16. Confidentiality measures and system adopted for the transaction 17. Statement on assets purchase and sale within 12 months prior to the transaction 18. Full authorization to the board to handle matters regarding the transaction 19. Statement on whether there is a direct or indirect paid employment of other third-party institutions or individuals for the transaction 20. Expansion of the Company's business scope and amendments to the Company's articles of association 21. Audit report with an extended period and pro forma audit report related to the transaction 22. Report (revised draft) on major assets purchase and its summary 23. Termination of some projects financed with raised funds and change of the purpose of some raised funds

Provided by Shenzhen Stock Exchange

Full Translation

AI Translation· gemini_document

Securities Code: 002932

Securities Abbreviation: *ST Mind

Announcement Number: 2026-060

Wuhan Mind Biological Technology Co., Ltd.

Announcement on Supplementing the Notice of the First Extraordinary General Meeting of 2026 and Adding Provisional Proposals

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from false representations, misleading statements, or material omissions.

On July 24, 2026, Wuhan Mind Biological Technology Co., Ltd. (hereinafter referred to as the "Company") held the eighth meeting of the fifth Board of Directors, which deliberated and passed the "Proposal on Requesting the Convening of the First Extraordinary General Meeting of 2026." The meeting decided to convene the Company's First Extraordinary General Meeting of 2026 on August 13, 2026. For details, please refer to the "Notice on Convening the First Extraordinary General Meeting of 2026" (Announcement Number: 2026-054) disclosed by the Company on July 25, 2026, on the Juchao Information Network (http://www.cninfo.com.cn) and the Securities Times.

On July 31, 2026, the Company's Board of Directors received a written letter from Ms. Chen Lili, the controlling shareholder of the Company, requesting to add provisional proposals to the First Extraordinary General Meeting of 2026. To improve meeting efficiency and reduce meeting costs, Ms. Chen Lili proposed that the proposals related to the major asset restructuring deliberated and approved at the seventh meeting of the fifth Board of Directors and the proposals deliberated and approved at the ninth meeting of the fifth Board of Directors be submitted to this general meeting for deliberation as provisional proposals. For details, please refer to the relevant documents disclosed by the Company on June 30, 2026, and August 1, 2026, on the Juchao Information Network (http://www.cninfo.com.cn) and the Securities Times.

In accordance with the "Guidelines for Self-Regulation of Listed Companies on the Shenzhen Stock Exchange No. 1 - Standardized Operation of Main Board Listed Companies," the "Articles of Association of Listed Companies," and the "Company's Articles of Association," shareholders who individually or collectively hold more than 1% of the Company's shares (including preferred shares with voting rights restored, etc.) can submit provisional proposals in writing to the convener 10 days before the general meeting. As of the disclosure date of this announcement, Ms. Chen Lili holds 62,918,895 shares of the Company, accounting for 27.06% of the Company's total share capital. Her proposal qualification meets the relevant requirements. The provisional proposal was submitted to the Company's Board of Directors in writing 10 days before the general meeting, and the provisional proposal has a clear agenda and specific resolution matters, falling within the scope of the Board of Directors' authority as stipulated in the "Company's Articles of Association." The proposal procedures and content comply with relevant laws, regulations, and the "Company's Articles of Association." The Company's Board of Directors agrees to submit the aforementioned provisional proposals for deliberation at the Company's First Extraordinary General Meeting of 2026. Except for the above adjustments, the "Notice on Convening the First Extraordinary General Meeting of 2026" disclosed by the Company on July 25, 2026, regarding the various matters of the general meeting remains unchanged. This announcement serves as a supplementary notice.

Details of the First Extraordinary General Meeting of 2026

1. Basic Information of the Meeting

1. Name of the Meeting: First Extraordinary General Meeting of 2026

2. Convener: Board of Directors (Fifth Board of Directors, Eighth Meeting)

3. Compliance with Laws and Regulations: This meeting is convened in accordance with the "Company Law of the People's Republic of China," "Securities Law of the People's Republic of China," "Guidelines for Self-Regulation of Listed Companies on the Shenzhen Stock Exchange No. 1 - Standardized Operation of Main Board Listed Companies," "Articles of Association of Listed Companies," and other relevant laws, regulations, and the "Company's Articles of Association."

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.